Combined sales of the three most lucrative cannabis pharmaceuticals products – Epidiolex®, Dronabinol, and Sativex® – are set to reach €1.8 billion by 2025, according to a new report. The Pharmaceutical Cannabis Report: 2nd Edition, released today by global cannabis industry consultants Prohibition Partners, finds that research on the endocannabinoid system is one of the most promising – and potentially lucrative – avenues for new therapeutics in medicine at the moment. The report highlights how the use of cannabinoids in the treatment of medical conditions, from pain and spasticity to PTSD and epileptic seizures, offers major opportunities, with the current global spend on non-cannabinoid-based pain medications worldwide estimated at US$63-85 billion each year. To date, no single cannabinoid-based drug has received widespread approval for the treatment of pain, despite the fact that this is by far the most common condition for which medical cannabis is used. The market for pharmaceutical products which leverage the endocannabinoid system to treat illness remains largely untapped.
Mmp News Author, Medical Marijuana Program Connection, 09/08/2021 12:50:00